Find Funding Opportunities

Notice NINDS' Participation PA-18-373 Mentored Clinical Scientist Research Career Development Award Parent K08 - Independent Clinical Trial Allowed)" Notice Number: NOT-NS-18-023 Key Dates Release Date: December 11, 2017 Related Announcements PA-18-373 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to inform potential applicants the National Institute Neurological Disorders Stroke NINDS) participate, effective immediately, PA-18-373 quot;Mentored Clinical Scientist Research Career Development Award Parent K08 - Independent Clinical Trial Allowed)". following italicized changes made indicate participation NINDS this FOA.  Part 1. Overview Information Components Participating Organizations National Cancer Institute NCI) National Eye Institute NEI) National Heart, Lung, Blood Institute NHLBI) National Human Genome Research Institute NHGRI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) National Institute General Medical Sciences NIGMS) National Institute Mental Health NIMH) National Institute Minority Health Health Disparities NIMHD) National Center Complementary Integrative Health NCCIH) National Institute Neurological Disorders Stroke NINDS) Catalog Federal Domestic Assistance CFDA) Number(s) 93.121; 93.307; 93.853; 93.286; 93.865; 93.242; 93.867; 93.398; 93.273; 93.233; 93.840; 93.839; 93.838; 93.837; 93.398; 93.213; 93.279; ; 93.173; 93.172; 93.866; 93.853 nbsp; other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Stephen Korn, Ph.D. National Institute Neurological Disorders Stroke Telephone: 301-496-188 Email: korns@mail.nih.gov

Notice NINDS' Participation PA-18-371 Independent Scientist Award Parent K02 - Independent Clinical Trial Allowed)" Notice Number: NOT-NS-18-024 Key Dates Release Date: December 11, 2017 Related Announcements PA-18-371 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to inform potential applicants the National Institute Neurological Disorders Stroke NINDS) participate, effective immediately, PA-18-371 quot;Independent Scientist Award Parent K02 - Independent Clinical Trial Allowed)". following italicized changes made indicate participation NINDS this FOA.  Part 1. Overview Information Components Participating Organizations National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Dental Craniofacial Research NIDCR) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) National Institute Neurological Disorders Stroke NINDS) Catalog Federal Domestic Assistance CFDA) Number(s) 93.113; 93.866; 93.273; 93.279; 93.121; 93.853 nbsp;  other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Stephen Korn, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-188 Email: korns@mail.nih.gov

Notice NINDS' Participation PA-18-375 Mentored Patient-Oriented Research Career Development Award Parent K23 - Independent Clinical Trial Allowed)" Notice Number: NOT-NS-18-025 Key Dates Release Date: December 8, 2017 Related Announcements PA-18-375 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to inform potential applicants the National Institute Neurological Disorders Stroke NINDS) participate, effective immediately, PA-18-375 quot;Mentored Patient-Oriented Research Career Development Award Parent K23 - Independent Clinical Trial Allowed)". following italicized changes made indicate participation NINDS this FOA.  Part 1. Overview Information Components Participating Organizations National Eye Institute NEI) National Heart, Lung, Blood Institute NHLBI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Allergy Infectious Diseases NIAID) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) National Institute General Medical Sciences NIGMS) National Institute Mental Health NIMH) National Institute Nursing Research NINR) National Institute Minority Health Health Disparities NIMHD) National Center Complementary Integrative Health NCCIH) National Institute Neurological Disorders Stroke NINDS) Catalog Federal Domestic Assistance CFDA) Number(s) 93.307; 93.286; 93.865; 93.859; 93.113; 93.242; 93.867; 93.855; 93.213; 93.361; 93.866; 93.273; 93.847; 93.233; 93.840; 93.839; 93.838; 93.837; 93.279; 93.121; 93.173; 93.853 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Stephen Korn, Ph.D. National Institute Neurological Disorders Stroke Telephone: 301-496-188 Email: korns@mail.nih.gov nbsp;

Notice NINDS' Participation PA-18-398 NIH Pathway Independence Award Parent K99/R00 - Independent Clinical Trial Allowed)" Notice Number: NOT-NS-18-026 Key Dates Release Date: December 8, 2017 Related Announcements PA-18-398 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to inform potential applicants the National Institute Neurological Disorders Stroke NINDS) participate, effective immediately, PA-18-398 quot;NIH Pathway Independence Award Parent K99/R00 - Independent Clinical Trial Allowed)." following italicized changes made indicate participation NINDS this FOA.  Part 1. Overview Information Components Participating Organizations National Cancer Institute NCI) National Eye Institute NEI) National Heart, Lung, Blood Institute NHLBI) National Human Genome Research Institute NHGRI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) National Institute General Medical Sciences NIGMS) National Institute Mental Health NIMH) National Institute Nursing Research NINR) National Institute Minority Health Health Disparities NIMHD) National Library Medicine NLM) National Center Complementary Integrative Health NCCIH) National Center Advancing Translational Sciences NCATS) Division Program Coordination, Planning Strategic Initiatives, Office Research Infrastructure Programs ORIP) National Institute Neurological Disorders Stroke NINDS) Catalog Federal Domestic Assistance CFDA) Number(s) 93.351; 93.121; 93.307; 93.286; 93.865; 93.859; 93.113; 93.242; 93.867; ? 93.879; 93.855; 93.213; 93.361; 93.866; 93.273; 93.847; 93.172; 93.233; 93.840; 93.839; 93.839; 93.838; 93.837; 93.279; ; 93.121; 93.398; 93.173, 93.846, 93.853 other aspects this FOA remain unchanged Inquiries Please direct inquiries to: Stephen Korn, Ph.D. National Institute Neurological Disorders Stroke Telephone: 301-496-188 Email: korns@mail.nih.gov

Notice Intent Publish Funding Opportunity Announcement Analytical Clinical Validation Candidate Biomarkers Neurological Diseases U01) Notice Number: NOT-NS-18-015 Key Dates Release Date: December 5, 2017 Estimated Publication Date Funding Opportunity Announcement: 11/29/2017 First Estimated Application Due Date: 06/10/2018 Earliest Estimated Award Date: 02/10/2019 Earliest Estimated Start Date: 02/11/2019   Related Announcements PAR-18-664 PAR-18-550 PAR-18-548 PAR-18-549 Issued National Institute Neurological Disorders Stroke NINDS) Purpose NINDS intends launch new biomarker initiative publishing Funding Opportunity Announcements FOA) focused the analytical clinical validation candidate biomarkers neurological disorders conditions.  Notice being provided allow potential applicants sufficient time develop meaningful collaborations responsive projects. FOA expected be published April 2018 an expected application due date June 2018. FOA utilize U01 activity code.  Details the planned FOA provided below. Research Initiative Details Biomarkers become recognized critical the successful development effective therapeutics.  Despite active pace discovery novel biomarker candidates, few biomarkers progress through essential steps analytical clinical validation, robust, well-validated biomarkers use Phase II Phase III clinical trials remain scant. Thus, is critical need support clinical validation candidate biomarkers improve public health, particularly disorders the nervous system where failures advance therapeutics discovery the market notorious.  NINDS biomarker initiative consists four primary components:  1) Leverage existing NIH-funded tissue data repositories, 2) Efforts better understand gaps biomarker discovery through scientific workshops, 3) Milestone-driven funding opportunities focused analytical clinical validation candidate biomarkers, 4) development an online website will provide one-stop shop” investigators an interest using resources applying funding biomarker research. funding opportunity announcement be milestone driven. FOA support analytical validation identified candidate biomarkers.  degree validation depend upon context use the biomarker, using standards guidelines provided the FDA.  Applicants strongly encouraged consult NINDS program staff below) plans an application being developed. Funding Information Estimated Total Funding   Expected Number Awards TBD Estimated Award Ceiling   Primary CFDA Numbers 93.853 Anticipated Eligible Organizations Public/State Controlled Institution Higher Education Private Institution Higher Education Nonprofit 501(c)(3) IRS Status than Institution Higher Education) Nonprofit without 501(c)(3) IRS Status than Institution Higher Education) Small Business For-Profit Organization than Small Business) State Government Indian/Native American Tribal Government Federally Recognized) County governments City township governments Special district governments Independent school districts Public housing authorities/Indian housing authorities Indian/Native American Tribally Designated Organization Native American tribal organizations than Federally recognized tribal governments) U.S. Territory Possession Indian/Native American Tribal Government than Federally Recognized) Non-domestic non-U.S.) Entity Foreign Organization) Regional Organization Applications not being solicited this time.   Inquiries Please direct inquiries to: Mary Ann Pelleymounter, Ph.D.  National Institute Neurological Disorders Stroke 301-451-4551 mary.pelleymounter@nih.gov  

Notice Intent Publish Funding Opportunity Announcement Analytical Clinical Validation Candidate Biomarkers Neurological Disease U01) Notice Number: NOT-NS-18-020 Key Dates Release Date: December 4, 2017 Estimated Publication Date Funding Opportunity Announcement: 11/29/2017 First Estimated Application Due Date: 06/10/2018 Earliest Estimated Award Date: 02/10/2019 Earliest Estimated Start Date: 02/11/2019 Related Announcements PAR-18-664 PAR-18-550 PAR-18-548 PAR-18-549 Issued National Institute Neurological Disorders Stroke NINDS) Purpose NINDS intends launch second biomarker initiative publishing Funding Opportunity Announcement FOA) focused the analytical clinical validation candidate biomarkers neurological disorders conditions. Notice being provided allow potential applicants sufficient time develop meaningful collaborations responsive projects.  FOA expected be published April 2018 an expected application due date June 2018 FOA utilize U01 activity code. Details the planned FOA provided below. Research Initiative Details Biomarkers become recognized critical the successful development effective therapeutics.  Despite active pace discovery novel biomarker candidates, few biomarkers progress through essential steps analytical clinical validation, robust, well-validated biomarkers use Phase II Phase III clinical trials remain scant. Thus, is critical need support clinical validation candidate biomarkers improve public health, particularly disorders the nervous system where failures advance therapeutics discovery the market notorious.  NINDS biomarker initiative consists four primary components:  1) Leverage existing NIH-funded tissue data repositories, 2) Efforts better understand gaps biomarker discovery through scientific workshops, 3) Milestone-driven funding opportunities focused analytical clinical validation candidate biomarkers, 4) development an online website will provide one-stop shop” investigators an interest using resources applying funding biomarker research. funding opportunity announcement be milestone driven. FOA support clinical validation evaluation clinical utility candidate biomarkers.  degree validation depend upon context use the biomarker, using standards guidelines provided the FDA.  Applicants strongly encouraged consult NINDS program staff below) plans an application being developed. Funding Information Estimated Total Funding   Expected Number Awards TBD Estimated Award Ceiling   Primary CFDA Numbers 93.853 Anticipated Eligible Organizations Public/State Controlled Institution Higher Education Private Institution Higher Education Nonprofit 501(c)(3) IRS Status than Institution Higher Education) Nonprofit without 501(c)(3) IRS Status than Institution Higher Education) Small Business For-Profit Organization than Small Business) State Government Indian/Native American Tribal Government Federally Recognized) County governments City township governments Special district governments Independent school districts Public housing authorities/Indian housing authorities Indian/Native American Tribally Designated Organization Native American tribal organizations than Federally recognized tribal governments) U.S. Territory Possession Indian/Native American Tribal Government than Federally Recognized) Non-domestic non-U.S.) Entity Foreign Organization) Regional Organization Applications not being solicited this time.   Inquiries Please direct inquiries to: Mary Ann Pelleymounter, Ph.D.  National Institute Neurological Disorders Stroke 301-451-4551 mary.pelleymounter@nih.gov  

Request Information RFI): Well Characterized Brain Bank Resources Alzheimer's Disease-Related Dementias ADRD) PET Ligand development Cryo-EM Structural Analysis Protein Species. Notice Number: NOT-NS-18-018 Key Dates Release Date: November 30, 2017 Related Announcements None Issued National Institute Neurological Disorders Stroke NINDS) Purpose National Institute Neurological Disorders Stroke NINDS) seeks brain tissue resource information new ADRD initiatives will focus the development PET ligands Alzheimer’s Disease Related Dementias ADRDs) Cryo-Electron Microscopy Cryo-EM) structural analysis protein species related ADRD pathogenesis. Resources identified through RFI be posted the NINDS Resource webpage investigators applying the new ADRD initiatives be encouraged integrate resources through collaborations their research plan. Background   2016, NINDS organized conference Alzheimer's Disease Related Dementias ADRDs) focused on  frontotemporal degeneration FTD), Lewy body dementias LBD) including dementia Lewy bodies DLB) Parkinson disease dementia PDD), vascular contributions cognitive impairment dementia VCID), mixed diseases including associated diagnostic challenges multiple etiology dementias MED), issues related health disparities. conference complemented National Institute Aging’s ldquo;Alzheimer’s Disease Research Summit 2015: Path Treatment Prevention.” Both conferences responded the National Alzheimer’s Project Act was signed law January 2011. objective the ADRD conference to contribute the efforts directed preventing effectively treating Alzheimer’s disease, including Alzheimer’s disease-related dementias, 2025.  Alzheimer’s Disease-Related Dementias steering committee solicited input internationally recognized experts develop prioritized recommendations guide scientific research the next 5 10 years.  Cross-cutting recommendations the ADRD working groups focused basic science biomarker developments can further our understanding protein species associated ADRD pathogenesis, well to advance tool development.  Biomarker development crucial patient stratification disease progression.  Although recent advances Tau PET ligand development look promising Alzheimer’s disease, specificity selectivity PET ligands non-AD tauopathies not yet achieved PET ligands alpha-synuclein TDP43 still elusive. accelerate development characterization PET ligands structural analyses ADRD protein species related disease pathogenesis, NINDS requests information human postmortem biopsy) brain tissue would available sharing the research community.  Tissue be shared ideally linked de-identified clinical data e.g., neurological, neuropsychological neuroimaging data) the development these tools resources.  Typically, several grams tissue depending the pathogenic protein load brain region needed these studies. Information Requested NINDS invites researchers, clinicians programs collections well characterized brain tissue interested the development collaborations FY18 ADRD Funding Opportunity Announcements FOAs) submit information brain tissue associated de-identified clinical data availability. Key information regarding brain tissue collections associated de-identified clinical data available PET ligand development protein structural analysis include: Average post-mortem interval 10-76 hours desirable), available measures tissue quality e.g., tissue pH RIN) Availability frozen tissue number brains), average amount tissue available sharing respect brain region(s) provided; Method freezing e.g., flash frozen) Indication availability corresponding fixed tissue including nature duration fixation methods storing fixed tissue e.g., cryo-preservation); Antemortem clinical diagnosis, age diagnosis, age death, sex, ethnicity: Number brains genetic characterization – family history related neurologic diseases, known causative risk gene mutations, common genetic risk factors e.g., APOE, MAPT, GBA, GRN, C9ORF72, SCNA, etc.), availability whole exome genome data; and/or data genome-wide significant risk factors; Pathological characterization primary associated disease processes using consensus neuropathological criteria ADRD. Diagnostic criteria used Examples past sharing the resource Requirements resource sharing e.g. MOU, MTA any key restrictions Name individual email contact the brain tissue resource. to Submit Response Response this RFI must submitted ADRDTissueResources@ninds.nih.gov January 15th, 2017]. Responses should provided a narrative links pertinent supplemental information needed. attachments be accepted. proprietary, classified, confidential, sensitive information should included your response Responses this RFI voluntary. RFI seeks input planning purposes only should be construed a solicitation applications an obligation the part the Federal Government, National Institutes Health, individual NIH Institutes Centers. information collected not considered confidential. Processed results be shared internally with members health-related scientific work groups, will posted the NINDS Resource webpage, appropriate. NIH acknowledges receipt information submitted, will comment the content.   Inquiries Please direct inquiries to: Margaret Sutherland, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-5680 Email:sutherlandm@ninds.nih.gov

Countermeasures Against Chemical Threats CounterACT): Opportunities Opioid Research Notice Number: NOT-NS-18-019 Key Dates Release Date: November 27, 2017 Related Announcements PAR-15-315 PAR-16-330 PAR-16-331 Issued National Institute Neurological Disorders Stroke NINDS) National Institute Drug Abuse NIDA) Purpose purpose this notice to highlight NIH/NINDS Countermeasures Against Chemical Threats CounterACT) program's interest developing safe effective therapeutics would prevent morbidity mortality following exposure the opioids fentanyl, carfentanil, acetylfentanyl, alfentanil, and/or diacetylmorphine heroin). program concentrates developing therapeutics treat and/or prevent injuries deaths may result exposure chemical threats a variety scenarios. Applications being accepted under three specific Funding Opportuntiy Announcements FOAs) issued the NIH CounterACT program PAR-15-315, PAR-16-330, PAR-16-331). be considered appropriate these FOAs, applications must follow instructions general descriptions found these FOAs well the following requirements related the specialized mission the NIH CounterACT program. Research supported these FOAs must relevant chemical emergencies where general civilian population might exposed opioids. research might include industrial accidents, natural disasters causing casualties, deliberate attacks again civilians. examples research could supported include, are limited to, following: Safety efficacy studies naloxone other FDA-approved drugs use against opioids listed above, especially they relate potential respiratory problems Safety efficacy studies naloxone other FDA-approved drugs use against opioids listed above these opioids administered a method consistent a deliberate attack against civilians, by industrial accidents natural disasters causing mass casualties e.g. aerosolized, food water, etc.) opioid overdose antidotes greater safety efficacy naloxone other FDA- approved drugs match higher potency fentanyl analogues, including naloxone-related antidotes those based new therapeutic targets Antidotes longer half-lives that multiple doses not needed rapid succession, many people be treated once during mass casualty event; includes increases serum half-life well alteration degradative metabolism Single antidotes acceptable activity against least or of opioids listed above NIH CounterACT program support exploratory developmental research PAR-15-315) well the identification PAR-16-330) optimization PAR-16-331) therapeutic lead compounds. Potential applicants should the descriptions scientific scope found these FOAs. Applicants strongly urged contact NIH representatives listed below prior submission. Inquiries Please direct general NIH CounterACT inquiries to: David A. Jett, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-6035 Email: david.jett@nih.gov Please direct specific opioid research inquiries: Kristopher J. Bough, Ph.D. National Institute Drug Abuse NIDA) Telephone: 301-443-9800 Email: boughk@nih.gov nbsp;

Notice Informational Webinar Using Parent T32 Funding Opportunity Announcement PA-18-403) Create NINDS-Targeted Institutional Translational Training Programs Notice Number: NOT-NS-18-021 Key Dates Release Date: November 27, 2017 Related Announcements None Issued National Institute Neurological Disorders Stroke NINDS) Purpose Notice to inform potential applicants an upcoming informational webinar using parent T32 PA-18-403) its reissues support NINDS-targeted institutional training programs translational research.  NINDS welcomes applications the parent T32 institutional training programs basic, clinical translational research falls within NINDS mission. NINDS currently receives few applications translational training programs. Consequently, NINDS hosting webinar discuss approaches potential applicants might to develop training programs designed equip trainees expertise basic clinical research well an understanding the translational processes used advance basic clinical research potential therapies. webinar cover creation training environments involve basic clinical researchers working concert address research problems an eye toward development viable health-relevant therapies, technologies, devices.  webinar recommended established investigators expertise insights translational research are interested learning the NINDS philosophy creating T32 institutional training programs. webinar optional not required submission applications. WEBINAR INFORMATION Informational Webinar Using Parent T32 Funding Opportunity Announcement PA-18-403) Create NINDS-Targeted Institutional Translational Training Programs January 18, 2018 11 a.m.- noon Eastern Time Please visit following link register the webinar: Link webinar registration button available the bottom the page. Inquiries Please direct inquiries to: Stephen J. Korn, Ph.D. National Institute Neurological Disorders Stroke Email: korns@ninds.nih.gov

Notice Change Application Due dates PAR-17-001 Emerging Global Leader Award K43)" Notice Number: NOT-TW-18-001 Key Dates Release Date: November 8, 2017 Related Announcements PAR-17-001 Issued Fogarty International Center FIC) National Cancer Institute NCI) National Human Genome Research Institute NHGRI) National Institute Dental Craniofacial Research NIDCR) National Institute Environmental Health Sciences NIEHS) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) Office Research Women’s Health ORWH) Purpose purpose this Notice to inform scientific community changes the Application Due Dates for PAR-17-001 "Emerging Global Leader Award K43)". Due a technical error the NIH guide, potential applicants have seen incorrect version the FOA application due dates were longer valid. fairness those may seen incorrect dates are modifying quot;Key Dates" section below. Applicants have already submitted grant application the option withdraw resubmit the new deadline. Part 1. Overview Information Key Dates Current Key Dates Letter Intent Due Date: 30 days before application due date Application Due Date(s): December 14, 2016; November 7, 2017; November 7, 2018 AIDS Application Due Date(s): December 14, 2016; November 7, 2017; November 7, 2018 Scientific Merit Review: March 2017, March 2018, March 2019 Advisory Council Review: 2017, 2018, 2019 Earliest Start Date: July 2017, July 2018, July 2019 Expiration Date: November 8, 2018 Modified Key Dates Letter Intent Due Date: 30 days before application due date Application Due Date(s): December 14, 2016; December 14, 2017; and November 7, 2018 AIDS Application Due Date(s): December 14, 2016; December 14, 2017; November 7, 2018 Scientific Merit Review: March 2017, March 2018, March 2019 Advisory Council Review: May 2017, 2018, 2019 Earliest Start Date: July 2017, July 2018, July 2019 Expiration Date: November 8, 2018 Inquiries Please direct inquiries to: Christine Jessup, Ph.D Fogarty International Center FIC) Telephone: 301-496-1653  Email: Christine.Jessup@nih.gov nbsp;